Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2000-01-10
2001-07-17
Bernhardt, Emily (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S376000
Reexamination Certificate
active
06262056
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the synthesis of new benzothiophene derivatives, the salts, optical isomers and polymorphs thereof, having the general formula (1)
as also to the corresponding pharmaceutical compositions and the use thereof in the preparation of these pharmaceutical compositions for the treatment of neurological disorders and, in particular, for the treatment of anxiety and/or depression, as being antidepressants having a dual activity: inhibition of serotonin reuptake and having affinity for the 5-HT
1A
receptor.
BACKGROUND OF THE INVENTION
Drugs for the treatment of depression have been available for over 30 years. Both the first monoamino oxidase inhibitor (MAO inhibitor), iproniazide, and the first tricyclic antidepressant (T.ACA), imipramine, were placed on the market at the end of the 50's. The second generation antidepressants represent a considerable improvement on the traditional tricyclic antidepressants, or on the irreversible unspecific MAO inhibitors. In spite of this, they still offer side effects, and what is more important, the latency time until the therapeutic effect appears is still too long for the treatment to be deemed optimal.
The latest class of antidepressants placed on the market was the one comprising the selective serotonin reuptake inhibitors, outstanding among which are fluoxetine (Lilly ES433720), paroxetine (Ferrosan, ES422734) and sertraline (Pfizer, ES496443). The products of this class have a high degree of structural diversity in comparison with other types of serotonin reuptake inhibitors, such as may be the tricyclic antidepressants. In spite of their structural variety, these compounds are highly selective for the serotonin receptor. In fact, their binding to &agr; and &bgr; adrenergic, dopaminergic., histamine and muscarine receptors is insignificant. It is postulated that this could be due to a great structural similarity to the pharmacophore, which is responsible for their specificity, and relative affinity to the corresponding serotonin receptor.
Among the most frequent adverse effects of the serotonin reuptake inhibitors are those related with gastrointestinal disorders. The majority of them also cause inhibition of the hepatic metabolism of other drugs with the corresponding pharmaco-dynamic interactions and have a retarded onset of their antidepressive action.
With this background in mind, there arises the need to continue investigating so as to create a third generation of antidepressants. The four points that an antidepressant must fulfil to be considered as a member of the third generation are:
1. Faster action
2. Broader efficacy
3. Less side effects
4. Safer in case of overdose
The first of these four points is the one offering the greatest challenge in antidepressant research since the harm that it represents for a depression patient that the drug does not start to show its effects until the elapse of several weeks after the start of the treatment is obvious.
The reason why the ailment takes time to remit, after treatment with monoamine reuptake inhibitors, appears to be due to a process of desensitisation of the presynaptic 5-HT
1A
receptors, which means that the serotoninergic tone is reduced until this desensitisation has occurred.
It may be gathered from all the above that an antidepressive treatment which, further to inhibiting the serotonin reuptake, were to involve a blocking or a rapid desensitisation of the 5-HT
1A
somatodentritic autoreceptors would increase the antidepressive effectiveness, on allowing the serotonin concentration in the serotoninergic terminations to rise quickly. In this sense, there has been proposed the simultaneous administration of serotonin reuptake inhibitors with selective 5-HT
1A
receptor antagonists, such as pindolol (Artigas F. et al., Arch. Gen. Psychiatry, 51, 248-251 (1994); Blier P. et al., J. Clin. Pharmacol. 15, 217-222 (1995)) to facilitate the quickest possible onset of the antidepressive effect. This theory has led the researchers suggest that the addition of products blocking the 5-HT
1A
type autoreceptors may prevent the onset of this negative feedback system and potentiate the effect of the serotonin reuptake inhibitors.
One Lilly patent (EP 0 687 472) claims the potentiation of the effect of the serotonin reuptake inhibitors by increasing the availability of certain brain neurotransmitters (serotonin among them) by combining the serotonin reuptake inhibitors with selective 5-HT
1A
receptor antagonists.
Bearing the above background in mind, it is therefore an object of this invention to synthesise compounds having this dual activity, i.e., serotonin reuptake inhibitors with affinity for the 5-HT
1A
receptor.
The invention relates in particular to the synthesis and pharmacological activity of new benzothiophene derivatives of the general formula (
1
).
Products to some extent similar to those disclosed here have been claimed in the literature. Thus, for example, U.S. Pat. No. 2,979,507 claims products having the general formula:
To be precise, there are disclosed the products:
where R may be H or 2-OCH
3
among others.
The document EP 0 596 120 claims products of the general formula:
where X is generally: —S, or S(O)— but may be, among others: —C(O)—; —CH(OR)—; —C(N—OR)—; —CH(NH
2
—; A may be an alkylene group and T is generally a 1,2-benzoisoxazole or 1,2-benzothiazole ring, but may be any other aromatic ring. Nevertheless, the above document does not contemplate the possibility of R
1
and R
2
jointly forming a ring, whereby the products claimed do not include benzothiophenes.
The document GB 1096341 discloses products of the general formula
where R may be: —CH
2
—CH
2
—C(O)—Ar and Ar may be, among others, a thiophene ring, although not a benzothiophene ring.
To be precise, the above patent describes the products:
where R
1
is 2-F or 4-F or 4-Cl.
U.S. Pat. No. 3,002,976 claims compounds of the general formula:
where R is H, methyl or halogen.
The documents WO 9616052 and WO 9615792, describe products of general formula:
where Z is N or CH, and Ar
1
may be a benzothiophene ring. In these compounds the aromatic ring (Ar
2
) is not directly attached to the piperazine ring, but through a spacer X (CH
2
, CO, etc.), unlike the compounds of the present invention.
The document DE 2360545 describes piperazines including the compound:
benzothiophene which, like the above named compounds, does not have the aromatic ring directly attached to the piperazine.
DESCRIPTION OF THE INVENTION
As stated above, the object of the present invention are new benzothiophene derivatives of the general formula (
1
), and the corresponding compositions and the use thereof for obtaining compositions having a pharmacological activity.
where
Z is: —CO—, —CH(OR
6
)—, —C(NOR
7
)—;
R
1
is: H, low molecular weight alkyl, halogen, or —OR
8
;
R
2
and R
3
are independent and stand for: H, C
1
-C
6
alkyl, halogen, —OR
8
, nitro, cyano, NR
9
R
10
, —COR
8
, —CO
2
R
8
, —SO
2
NR
9
R
10
, —SO
2
R
8
, —SR
8
,—CONR
9
R
10
;
R
4
and R
5
are the same or different and each stands for: H, C
1
-C
6
alkyl, halogen, haloalkyl, —OR
8
, nitro, NR
9
R
10
; —COR
8
; CO
2
—R
8
; —SO
2
NR
9
R
10
; —SO
2
R
8
; SR
8
, cyano; —CONR
9
R
10
or R
4
and R
5
may form together a benzene ring fused to the phenyl ring;
R
6
is: H, C
1
-C
6
alkyl, CO
2
R
8
, —C(O)NR
9
R
10
, naphthyl or phenyl optionally substituted by one or more substituents selected from among the following: H, haloalkyl, C
1
-C
6
alkyl, halogen, C
1
-C
6
alkoxy, methylenedioxy, nitro, cyano;
R
7
is: H or C
1
-C
6
alkyl;
R
8
is H, low molecular weight alkyl or phenyl;
R
9
and R
10
are independent and stand for: H, low molecular weight alkyl or phenyl or R
9
and R
10
together with the N to which they are attached form a 5- or 6-membered ring in which there may optionally be an N, O or S.
The invention also comprises the physiologically acceptable salts, solvates and salts of the solvates of the formula (1) compounds and which include the acid addition salts formed with inorganic and organi
Bosch Rovira Anna
Del Castillo Nieto Juan Carlos
Del Rio Zambrana Joaquín
Lasheras Aldaz Berta
Monge Vega Antonio
Bernhardt Emily
Sughrue Mion Zinn Macpeak & Seas, PLLC
Vita-Invest, SA
LandOfFree
Benzothiophene derivatives and corresponding use and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzothiophene derivatives and corresponding use and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzothiophene derivatives and corresponding use and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2463928